Sanofi Receives European Commission Approval For Wayrilz To Treat Immune Thrombocytopenia In Adults

Benzinga · 2d ago

The European Commission has approved Wayrilz (rilzabrutinib), a novel, oral, reversible, Bruton's tyrosine kinase (BTK) inhibitor, as a new treatment for immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments. This follows the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Wayrilz can help address the underlying causes of ITP through multi-immune modulation, targeting different pathways across the immune system.